A novel circRNA-miRNA-mRNA network revealed exosomal circ-ATP10A as a biomarker for multiple myeloma angiogenesis

References

• Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049–3058.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3(1):17046.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Reale A, et al. Angiogenesis in multiple myeloma. Chem Immunol Allergy. 2014;99:180–196.
   PubMedGoogle Scholar
• Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–2216.
   PubMed Web of Science ®Google Scholar
• Alzrigat M, Parraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: from mechanisms to therapy. Semin Cancer Biol. 2018;51:101–115.
   PubMed Web of Science ®Google Scholar
• Lamanuzzi A, Saltarella I, Frassanito MA, et al. Thrombopoietin promotes angiogenesis and disease progression in patients with multiple myeloma. Am J Pathol. 2021;191(4):748–758.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li S, Wang X, et al. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin. J Exp Clin Cancer Res. 2019;38(1):427.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082–4085.
   PubMed Web of Science ®Google Scholar
• Guryanov I, Tennikova T, Urtti A. Peptide inhibitors of vascular endothelial growth factor a: current situation and perspectives. Pharmaceutics. 2021;13(9):1337.
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;368(6489):367.
   PubMed Web of Science ®Google Scholar
• Mathieu M, Martin-Jaular L, Lavieu G, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9–17.
   PubMed Web of Science ®Google Scholar
• Wang J, Hendrix A, Hernot S, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555–566.
   PubMed Web of Science ®Google Scholar
• Umezu T, Tadokoro H, Azuma K, et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):3748–3757.
   PubMed Web of Science ®Google Scholar
• Chen T, Moscvin M, Bianchi G. Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment. Front Oncol. 2020;10:608815.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Li YC, Geng CY, et al. Serum exosomal microRNAs as novel biomarkers for multiple myeloma. Hematol Oncol. 2019;37(4):409–417.
   PubMed Web of Science ®Google Scholar
• Deng M, Yuan H, Liu S, et al. Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression. Cytotherapy. 2019;21(1):96–106.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang T, Xiao J. Circular RNAs: promising biomarkers for human diseases. EBioMedicine. 2018;34:267–274.
   PubMed Web of Science ®Google Scholar
• Gao M, Li C, Xiao H, et al. hsa_circ_0007841: a novel potential biomarker and drug resistance for multiple myeloma. Front Oncol. 2019;9:1261.
   PubMed Web of Science ®Google Scholar
• Gu C, Wang W, Tang X, et al. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021;20(1):84.
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang D, Zhou N, et al. Circular RNA protein tyrosine kinase 2 promotes cell proliferation, migration and suppresses apoptosis via activating MicroRNA-638 Mediated MEK/ERK, WNT/beta-catenin signaling pathways in multiple myeloma. Front Oncol. 2021;11:648189.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin Q, Song C, et al. Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade. Cancer Cell Int. 2020;20(1):383.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang L, Wu J, et al. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. J Exp Clin Cancer Res. 2019;38(1):54.
   PubMed Web of Science ®Google Scholar
• Chugh PE, Sin SH, Ozgur S, et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog. 2013;9(7):e1003484.
   PubMed Web of Science ®Google Scholar
• Maroto R, Zhao Y, Jamaluddin M, et al. Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses. J Extracell Vesicles. 2017;6(1):1359478.
   PubMed Web of Science ®Google Scholar
• Bachurski D, Schuldner M, Nguyen PH, et al. Extracellular vesicle measurements with nanoparticle tracking analysis - An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracell Vesicles. 2019;8(1):1596016.
   PubMed Web of Science ®Google Scholar
• Tang YT, Huang YY, Zheng L, et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. Int J Mol Med. 2017;40(3):834–844.
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang D, Wei W, et al. Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma. BMC Cancer. 2020;20(1):40.
   PubMed Web of Science ®Google Scholar
• Liu B, Li X, Liu F, et al. Expression and Significance of TRIM 28 in Squamous Carcinoma of Esophagus. Pathol Oncol Res. 2019;25(4):1645–1652.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59(3):728–733.
   PubMed Web of Science ®Google Scholar
• Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32(3):282–293.
   PubMed Web of Science ®Google Scholar
• Laubli H, Borsig L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 2019;10:2120.
   PubMed Web of Science ®Google Scholar
• Cluntun AA, Lukey MJ, Cerione RA, et al. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3(3):169–180.
   PubMed Web of Science ®Google Scholar
• Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013–1021.
   PubMed Web of Science ®Google Scholar
• Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451.
   PubMed Web of Science ®Google Scholar
• Boopathy GTK, Hong W. Role of Hippo Pathway-YAP/TAZ signaling in angiogenesis. Front Cell Dev Biol. 2019;7:49.
   PubMed Web of Science ®Google Scholar
• Wang X, Freire Valls A, Schermann G, et al. YAP/TAZ Orchestrate VEGF signaling during developmental angiogenesis. Dev Cell. 2017;42(5):462–78 e7.
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci. 2011;4:51.
   PubMed Web of Science ®Google Scholar
• Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7(1):11215.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673.
   PubMed Web of Science ®Google Scholar
• Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66(2):83–88.
   PubMed Web of Science ®Google Scholar
• Zhu J, Li B, Ji Y, et al. betaelemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1AVEGFA pathway based on network pharmacology. Oncol Rep. 2019;42(6):2561–2571.
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Paulis YW, Nowak-Sliwinska P, et al. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. J Pathol. 2018;246(4):447–458.
   PubMed Web of Science ®Google Scholar
• Katoh M. Therapeutics Targeting FGF Signaling Network in Human Diseases. Trends Pharmacol Sci. 2016;37(12):1081–1096.
   PubMed Web of Science ®Google Scholar
• Mulcrone PL, Edwards SKE, Petrusca DN, et al. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci Rep. 2020;10(1):17319.
   PubMed Web of Science ®Google Scholar
• Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137(9):1192–1195.
   PubMed Web of Science ®Google Scholar
• de Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020;130(10):5074–5087.
   PubMed Web of Science ®Google Scholar
• Chen RY, Yen CJ, Liu YW, et al. CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity. Cell Death Differ. 2020;27(4):1259–1273.
   PubMed Web of Science ®Google Scholar
• Tsutsui T, Kawahara H, Kimura R, et al. Glioma-derived extracellular vesicles promote tumor progression by conveying WT1. Carcinogenesis. 2020;41(9):1238–1245.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Pulkkinen HH, Kiema M, Lappalainen JP, et al. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. Angiogenesis. 2021;24(1):129–144.
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132.
   PubMed Web of Science ®Google Scholar
• Sun Y, Hou Z, Luo B, et al. Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429. Bioengineered. 2021;12(1):4159–4173.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu W, Tao G, et al. Circular RNA circ-LRP6 facilitates Myc-driven tumorigenesis in esophageal squamous cell cancer. Bioengineered. 2020;11(1):932–938.
   PubMed Web of Science ®Google Scholar